



# Ministero della Salute

DIREZIONE GENERALE DELLA PREVENZIONE SANITARIA

UFFICIO 5 PREVENZIONE DELLE MALATTIE TRASMISSIBILI E PROFILASSI INTERNAZIONALE

A

Assessorati alla Sanità Regioni  
Statuto ordinario e speciale

Assessorati alla Sanità Province  
Autonome Trento e Bolzano

U.S.M.A.F. – S.A.S.N.

Direzione Generale della programmazione  
sanitaria

Direzione Generale della sanità animale e dei  
farmaci veterinari

Direzione Generale per l'igiene e la sicurezza  
degli alimenti e la nutrizione

Direzione Generale dei dispositivi medici e del  
servizio farmaceutico

Direzione Generale della ricerca

Direzione Generale della comunicazione e dei  
rapporti europei e internazionali

AIFA

Ministero della difesa

Stato maggiore della difesa  
Ispettorato generale della sanità

Azienda ospedaliera - polo universitario ospedale  
Luigi Sacco

Federazione nazionale degli ordini dei medici  
chirurghi e degli odontoiatri

Comando carabinieri tutela della salute – NAS  
sede centrale

Istituto Superiore di Sanità

Croce rossa italiana  
Reparto nazionale di sanità pubblica

Istituto Nazionale per le Malattie Infettive –  
IRCCS “Lazzaro Spallanzani”

Istituto nazionale per la promozione della salute  
delle popolazioni migranti e per il contrasto delle  
malattie della povertà (INMP)

Componenti del Gruppo Tecnico di  
Coordinamento della Strategia nazionale di  
contrastodel'AMR

**OGGETTO: Rapid risk assessment ECDC: *Staphylococcus epidermidis* multi-resistente – 7  
novembre 2018.**

Lo *Staphylococcus epidermidis* è un comune stafilococco gram-positivo, coagulasi negativo (CoNS), normalmente parte della flora microbica presente sulla cute umana. Frequentemente contamina i campioni microbiologici e spesso è responsabile di infezioni correlate all'assistenza (ICA), soprattutto perché in grado di creare biofilm e contaminare dispositivi medici, come catetere venoso centrale, protesi valvolari o protesi ortopediche. Risulta essere, infatti, il più frequente agente eziologico di ICA in pazienti ricoverati in terapia intensiva in 11 Paesi dell'Unione Europea e la seconda causa di ICA associate a impianti artro-protesici.

Alcuni *S. epidermidis* si trasmettono in maniera predominante nei setting ospedalieri/assistenziali, diffondendosi tra ospedali e Paesi differenti. La capacità di formare biofilm vanifica l'azione di molti agenti antibatterici ed è tale da richiedere la sostituzione e la rimozione del dispositivo medico impiantato. Inoltre, gli *S. epidermidis* isolati in ambiente

assistenziale risultano essere resistenti a più antibiotici; in particolare, la resistenza alla meticillina è compresa tra il 75% e il 90% dei casi. Altrettanto elevata è la resistenza nei confronti di trimethoprim/sulfametossazolo, clindamicina, acido fusidico e fluorochinoloni.

L'antibiotico di scelta, attualmente, è la vancomicina, tuttavia sono stati isolati ceppi di *S. epidermidis* resistenti anche alla vancomicina.

Anche la rifampicina può essere utilizzata, in particolare per il trattamento di infezioni delle arto-protesi. Tuttavia, la terapia deve essere in combinazione con altri antibiotici verso cui sia stata evidenziata sensibilità, per la rapida capacità di sviluppare resistenza alla rifampicina quando usata in monoterapia.

Attualmente *S. epidermidis* mostra sensibilità in laboratorio anche a tigeciclina, ceftarolina, ceftobiprolo, dalbavancina, daptomicina, linezolid, oritavancina, quinupristin/dalfopristin, tedizolid e telavancin.

Numerosi sono i ceppi endemici di *S. epidermidis* multiresistenti diffusi a livello globale nei setting assistenziali. L'aumento rapido del fenomeno della multi-resistenza rappresenta un serio rischio a causa delle limitate opzioni di trattamento, soprattutto per le infezioni a partenza dai dispositivi permanenti e protesici, già difficili da trattare. Sebbene esistano alcuni agenti antimicobici attivi in vitro contro gli stafilococchi, l'esperienza clinica è ancora limitata.

Ulteriori studi epidemiologici in grado di valutare la distribuzione geografica dei ceppi di *S. epidermidis* multi-resistenti responsabili di infezione invasiva in pazienti suscettibili, nonché studi prospettici in vitro, in vivo e di correlazione sui risultati clinici, sono necessari al fine di chiarire l'impatto delle strategie terapeutiche.

Tuttavia, indipendentemente dai risultati di studi futuri, il crescente fenomeno di multi-resistenza dello *S. epidermidis*, anche ad agenti antimicobici attualmente considerati di prima linea, evidenzia la necessità di un loro uso prudente e quindi l'importanza dell'*antimicrobial stewardship*. Le scelte terapeutiche devono essere guidate dai dati di sorveglianza epidemiologica e dai dati di sensibilità/resistenza antimicobica dei campioni isolati da ciascun paziente. È altresì fondamentale attuare tutte le pratiche di prevenzione e controllo delle ICA, in particolare durante l'inserimento e l'uso di dispositivi medici.

Per ulteriori dettagli si può fare riferimento al Rapid risk assessment ECDC “*Staphylococcus epidermidis* multi-resistente – 7 novembre 2018”, fornito in allegato.

Si prega di dare la massima diffusione alla presente nota e al documento allegato presso le strutture sanitarie, inclusi presidi ed aziende ospedaliere.


Referente:

Dr.ssa Stefania Iannazzo

**IL DIRETTORE DELL'UFFICIO 5**

**\* F.to Francesco Maraglino**

**\*“firma autografa sostituita a mezzo stampa, ai sensi dell'art. 3, comma 2, del d. Lgs. N. 39/1993”**



## RAPID RISK ASSESSMENT

### Multidrug-resistant *Staphylococcus epidermidis*

07 November 2018

### Main conclusions and options for prevention and control

Several endemic multidrug-resistant *S. epidermidis* strains predominate across healthcare systems globally. Increases in the rate and breadth of resistance to multiple antimicrobial agents among these strains is a concerning trend that may limit treatment options for indwelling and prosthetic device infections that are already difficult to treat. Although there are a number of alternative antimicrobial agents that are active against staphylococci, clinical experience with these antimicrobial agents is still limited. Consequently, the precise significance for the therapeutic outcome in patients who have foreign devices (e.g. central vascular catheters, orthopaedic prosthetic devices and cerebrospinal fluid shunts) and surgical site infections of evolving resistance mechanisms that have been recently described in *S. epidermidis* is not yet fully characterised.

Further epidemiological studies of the geographical prevalence of multidrug-resistant *S. epidermidis* strains as a cause of invasive infection in susceptible patient populations as well as prospective *in vitro*, *in vivo* and clinical outcome correlation studies are needed to clarify their clinical impact on therapeutic outcomes of foreign-body infections. However in the majority of cases of *S. epidermidis* infections, removal or replacement of the contaminated medical device is already required in addition to antimicrobial therapy.

Irrespective of the findings of further studies, the increasing resistance of *S. epidermidis* to multiple antimicrobial agents that are currently considered as first-line agents for the treatment of *S. epidermidis* infections highlights the need for prudent use of them and therefore the importance of antimicrobial stewardship. Treatment options should be guided by local epidemiological surveillance data and individual antimicrobial susceptibility test results for each patient's isolates. Ensuring consistent application of proper infection prevention and control practices, particularly during the insertion and use of medical devices, is crucial for prevention of infections by *S. epidermidis*. More information on antimicrobial susceptibility testing against newer antimicrobial agents with activity against *S. epidermidis*, as well as better evaluation of their effectiveness, is necessary for the optimal management of *S. epidermidis* infections.

### Source and date of request

Request from the European Commission on 11 September 2018 – Ares(2018)4650114.

Suggested citation: European Centre for Disease Prevention and Control. Multidrug-resistant Staphylococcus epidermidis – 8 November 2018. Stockholm: ECDC; 2018.

## Public health issue

A recent article published in the journal Nature Microbiology, Global spread of three multidrug resistant lineages of *Staphylococcus epidermidis*, by J.Y.H. Lee et al. [1] reports a previously unrecognised international spread of near pandrug-resistant strains of *S. epidermidis* as a cause of infection in several countries including European Union (EU) Member States.

## Consulted experts

ECDC contributors (alphabetical order): Diamantis Plachouras (main contributor), Dominique Monnet, Marc Struelens

External experts (alphabetical order): Christian Giske (Karolinska University Hospital, Sweden), Guido Werner (Robert Koch Institute, Germany)

All experts have submitted declarations of interest and a review of these declarations did not reveal any conflict of interest.

## Disease background information

*Staphylococcus epidermidis* is the most common species of coagulase-negative staphylococci (CoNS) and is the most common species of normal human skin microbiota. *S. epidermidis* is a Gram-positive bacterium and able to form biofilms. A frequent skin coloniser, *S. epidermidis* commonly contaminates clinical microbiology samples, but is also a frequent cause of healthcare-associated infection. Due to the propensity to form biofilms, *S. epidermidis* is a leading cause of infections related to medical devices, such as central venous line-associated bloodstream infections, prosthetic valve endocarditis and surgical site infections (e.g. hip and knee prosthetic joint infections). CoNS were the most frequently identified cause of central line-associated bloodstream infections in surveillance of healthcare-associated infections acquired in intensive care units in 11 European Union (EU) Member States in 2015 [2] and the second-most common organism isolated from hip and knee prosthetic joint infections in surveillance of surgical site infections in the European Union/European Economic Area (EU/EEA) [3].

Specific strains of *S. epidermidis* can become predominant in hospital settings and have been shown to spread within hospitals [4] and between hospitals and countries [5,6]. Multilocus sequence typing (MLST) studies have demonstrated that several lineages predominate globally, with the most common lineages being ST2, ST5 and ST23. The modes of transmission of *S. epidermidis* in hospital settings are not well characterised since it is a ubiquitous commensal of the human skin and only acts as an opportunistic pathogen.

Healthcare-associated strains of *S. epidermidis* produce extracellular biofilms that hinder the action of most antimicrobial agents and host immune response, thus making treatment of medical device infections challenging and often requiring the replacement or removal of the contaminated device for successful treatment of the infection. Antimicrobial agents are administered concomitantly with replacement or removal of the device. Healthcare-associated strains of *S. epidermidis* tend to be multidrug-resistant, with resistance to meticillin ranging from 75% to 90% [7–9]. Resistance to other antimicrobial agents, such as trimethoprim/sulfamethoxazole, clindamycin, fusidic acid and fluoroquinolones is also very high. The antimicrobial agent of choice for most infections caused by *S. epidermidis* is vancomycin. Strains with decreased susceptibility or with resistance to vancomycin and the presence of subpopulations resistant to vancomycin (heteroresistance) have been commonly reported [10–12]. Heteroresistance to glycopeptides is not detected with standard antimicrobial susceptibility testing techniques and requires special methods such as the gradient diffusion macromethod or population-analysis profiling area under the concentration-time curve [13]. However, the clinical significance of heteroresistance is unknown [14–16]. Rifampicin is often recommended for the treatment of infections involving prosthetic devices due to activity against staphylococci in biofilms. However, rifampicin should always be used in combination with other active antimicrobial agents due to the rapid development of resistance to rifampicin when used as monotherapy [17]. Resistance of *S. epidermidis* to rifampicin is also commonly reported [18]. Several other antimicrobial agents remain active *in vitro* against *S. epidermidis*, such as ceftaroline, ceftobiprole, dalbavancin, daptomycin, linezolid, oritavancin, quinupristin/dalfopristin, tedizolid, telavancin and tigecycline. However, resistance to linezolid is increasingly reported, having spread among major predominant healthcare-associated lineages, and can be plasmid-mediated [19–21]. Resistance to the other listed antimicrobial agents is still uncommon.

Due to the challenges of treatment of medical device infections, consistent application of periprocedural infection prevention measures is crucial [22].

## Event background information

A comparative genomic study of 419 *S. epidermidis* clinical isolates from Australia, the EU (Belgium, Denmark, France, Germany, Ireland and the United Kingdom) and the US identified dual D471E and I527R *rpoB* gene mutations as a common mechanism related to rifampicin resistance and heteroresistance to glycopeptides that is prevalent among two common sequence types globally: ST2 and ST23 [1]. The study also describes an increasing prevalence of resistance to rifampicin among clinical *S. epidermidis* isolates from 2007 to 2017 in an Australian hospital and from 2012 and 2017 in a Belgian hospital. The study further confirmed the long-lasting predominance of a limited number of genetic lineages of multidrug-resistant *S. epidermidis* in hospital environments in Australia, the US and the above-mentioned EU Member States.

## ECDC threat assessment for the EU

Several endemic multidrug-resistant *S. epidermidis* strains predominate across healthcare systems globally. Increases in the rate and breadth of resistance to multiple antimicrobial agents among these strains is a concerning trend that may limit treatment options for indwelling and prosthetic device infections that are already difficult to treat. Although there are a number of alternative antimicrobial agents that are active against staphylococci, clinical experience with these antimicrobial agents is still limited. Consequently, the precise significance for the therapeutic outcome in patients who have foreign devices (e.g. central vascular catheters, orthopaedic prosthetic devices and cerebrospinal fluid shunts) and surgical site infections of evolving resistance mechanisms that have been recently described in *S. epidermidis* is not yet fully characterised.

Further epidemiological studies of the geographical prevalence of multiresistant *S.epidermidis* strains as a cause of invasive infection in susceptible patient populations, as well as prospective *in vitro*, *in vivo* and clinical outcome correlation studies, are needed to clarify their clinical impact on therapeutic outcomes of foreign body infections. However, in the majority of cases of *S. epidermidis* infections, removal or replacement of the contaminated medical device is already required in addition to antimicrobial therapy.

## Conclusions and options for prevention and control

The increasing resistance of *S. epidermidis* to multiple antimicrobial agents that are currently considered as first-line agents for the treatment of *S. epidermidis* infections highlights the need for prudent use of these agents and therefore the importance of antimicrobial stewardship. Treatment options should be guided by local epidemiological surveillance data and individual antimicrobial susceptibility test results for each patient's isolates. Ensuring consistent application of proper infection prevention and control practices, particularly during the insertion and use of medical devices, is crucial for prevention of infections by *S. epidermidis*. More information from antimicrobial susceptibility testing against newer antimicrobial agents with activity against *S. epidermidis*, as well as better evaluation of their effectiveness, is necessary for the optimal management of *S. epidermidis* infections.

## References

1. Lee JYH, Monk IR, Goncalves da Silva A, Seemann T, Chua KYL, Kearns A, et al. Global spread of three multidrug-resistant lineages of *Staphylococcus epidermidis*. *Nat Microbiol*. 2018 Oct;3(10):1175-85.
2. Plachouras D, Savey A, Palomar M, Moro M, Lebre A, McCoubrey J, et al., editors. Incidence and microbiology of central line-associated bloodstream infections in European intensive care units: Results from the European Healthcare-Associated Infections surveillance Network (HAI-Net). ePoster presented at: European Conference of Clinical Microbiology and Infectious Diseases (ECCMID); 24 April 2018; Madrid, Spain.
3. European Centre for Disease Prevention and Control. Healthcare-associated infections: surgical site infections. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC, 2018. Available from: <http://ecdc.europa.eu/publications-data/healthcare-associated-infections-surgical-site-infections-annual-0>.
4. Monsen T, Karlsson C, Wistrom J. Spread of clones of multidrug-resistant, coagulase-negative staphylococci within a university hospital. *Infect Control Hosp Epidemiol*. 2005 Jan;26(1):76-80.
5. Miragaia M, Couto I, Pereira SF, Kristinsson KG, Westh H, Jarlov JO, et al. Molecular characterization of methicillin-resistant *Staphylococcus epidermidis* clones: evidence of geographic dissemination. *J Clin Microbiol*. 2002 Feb;40(2):430-8.
6. Miragaia M, Thomas JC, Couto I, Enright MC, de Lencastre H. Inferring a population structure for *Staphylococcus epidermidis* from multilocus sequence typing data. *J Bacteriol*. 2007 Mar;189(6):2540-52.
7. Decousser JW, Desroches M, Bourgeois-Nicolaos N, Potier J, Jehl F, Lina G, et al. Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant *Staphylococcus aureus* from invasive infections. *Int J Antimicrob Agents*. 2015 Dec;46(6):622-30.
8. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. *J Antimicrob Chemother*. 2008 Nov;62 Suppl 2:ii65-74.
9. Otto M. *Staphylococcus epidermidis*--the 'accidental' pathogen. *Nat Rev Microbiol*. 2009 Aug;7(8):555-67.
10. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. *Antimicrob Agents Chemother*. 1998 Jan;42(1):100-7.
11. Nunes AP, Teixeira LM, Iorio NL, Bastos CC, de Sousa Fonseca L, Souto-Padron T, et al. Heterogeneous resistance to vancomycin in *Staphylococcus epidermidis*, *Staphylococcus haemolyticus* and *Staphylococcus warneri* clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. *Int J Antimicrob Agents*. 2006 Apr;27(4):307-15.
12. Tacconelli E, Tumbarello M, Donati KG, Bettio M, Spanu T, Leone F, et al. Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. *Clin Infect Dis*. 2001 Nov 15;33(10):1628-35.
13. Chong J, Quach C, Blanchard AC, Poliquin PG, Golding GR, Laferriere C, et al. Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant *Staphylococcus epidermidis* Outbreak in a Neonatal Intensive Care Unit. *Antimicrob Agents Chemother*. 2016 Oct;60(10):5673-81.
14. Berglund B, Claesson C, Nilsson LE, Hanberger H. High Prevalence of Heterogeneously Glycopeptide-Intermediate Coagulase-Negative Staphylococci in Sternal Wounds. *Antimicrob Agents Chemother*. 2016 Aug;60(8):5097-8.
15. Nam JR, Kim MS, Lee CH, Whang DH. Linezolid Treatment for Osteomyelitis due to *Staphylococcus Epidermidis* with Reduced Vancomycin Susceptibility. *J Korean Neurosurg Soc*. 2008 Jun;43(6):307-10.
16. Tevell S, Claesson C, Hellmark B, Soderquist B, Nilsson LE, Hanberger H. Heterogeneous glycopeptide intermediate *Staphylococcus epidermidis* isolated from prosthetic joint infections. *Eur J Clin Microbiol Infect Dis*. 2014 Jun;33(6):911-7.
17. Mandell GL, Moorman DR. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. *Antimicrob Agents Chemother*. 1980 Apr;17(4):658-62.
18. Cremniter J, Sivadon-Tardy V, Cailliez C, Bauer T, Porcher R, Lortat-Jacob A, et al. Genetic analysis of glycopeptide-resistant *Staphylococcus epidermidis* strains from bone and joint infections. *J Clin Microbiol*. 2013 Mar;51(3):1014-9.
19. Bender J, Strommenger B, Steglich M, Zimmermann O, Fenner I, Lensing C, et al. Linezolid resistance in clinical isolates of *Staphylococcus epidermidis* from German hospitals and characterization of two cfr-carrying plasmids. *J Antimicrob Chemother*. 2015;70(6):1630-8.

20. Doret L, Glaser P, Kassis-Chikhani N, Girlich D, Ichai P, Boudon M, et al. Long-lasting successful dissemination of resistance to oxazolidinones in MDR *Staphylococcus epidermidis* clinical isolates in a tertiary care hospital in France. *J Antimicrob Chemother.* 2018 Jan 1;73(1):41-51.
21. Layer F, Vourli S, Karavasilis V, Strommenger B, Dafopoulou K, Tsakris A, et al. Dissemination of linezolid-dependent, linezolid-resistant *Staphylococcus epidermidis* clinical isolates belonging to CC5 in German hospitals. *J Antimicrob Chemother.* 2018 May 1;73(5):1181-4.
22. World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. Geneva: WHO; 2016. Available from: <http://apps.who.int/iris/bitstream/handle/10665/250680/9789241549882-eng.pdf>.